The first Provider Webinar



Welcome to the **Final COVID-19 Vaccine Specific** Provider Webinar

Friday, September 29, 2023

9:00AM – 10:30AM

California Department of PublicHealth

Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.

Resource links will be dropped into, “Chat”

Housekeeping

Reminder to Panelists:

Please mute yourself when not speaking.

Please present on video today!

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:

Today's session is being recorded. Access today's slides and archived presentations at: EZIZ COVID Education

If you have post-webinar questions, please email leslie.amani@cdph.ca.gov

Friday Provider Webinar Transition Timeline

CDPH Immunization Branch Updates for Providers

10.6.23

CA COVID-19 Vaccination Program Updates and Provider Celebration! September 29

October Webinar Transition*: All Immunization topics available to all California Providers with special segments for BAP and VFC

September 2023 → October 2023

*Provider webinar cadence subject to change

Friday, December 4, 2020

Agenda

- Vaccine Updates
- Provider Enrollment
- Vaccine Distribution
- Data Reporting Requirements
- Ordering and Storage and Handling
- Resources
- Questions

From the Archives:
The agenda for the first California COVID-19 Provider Webinar

Since beginning, number of Friday Provider webinars estimated at 150 with attendees numbering close to 50,000!

Agenda: Friday, September 29, 2023

No.	Item	Speaker	Time (AM)
1	Welcome and Announcements	Leslie Amani (CDPH)	9:00 – 9:05
2	A Moment of Gratitude	Robert Schechter, MD (CDPH)	9:05 – 9:10
3	Potential Impacts: Federal Government Shutdown	Maria Volk (CDPH)	9:10 – 9:15
4	Vaccine Administration Data	Sharon Brummitt (CDPH)	9:15 – 9:20
5	Clinical Update	Caterina Liu, MD (CDPH)	9:20 – 9:25
6	COVID-19 Vaccine Access	Claudia Aguiluz (CDPH)	9:25 – 9:30
7	Storage and Handling	Katherine McHugh and Alan Hendrickson (CDPH)	9:30 – 9:35
8	Vaccine Management	Josh Pocus (My Turn) and Claudia Aguiluz (myCAvax)	9:35 – 9:40
9	COVID-19 Vaccine Quality Assurance	Eugene Beronilla and Francisco Borboa (CDPH)	9:40 – 9:45
10	COVID-19 Testing and Therapeutics	Jessica deJarnette, MD (CDPH)	9:45 – 9:50
11	COVID-19 Oral Antivirals Commercialization	Edward Salaguinto, PharmD, RPh (CDPH)	9:50 – 9:55
12	Resources	CDPH Subject Matter Experts	9:55 – 10:00
13	Sharing and Q&A	Attendees, SMEs, and Panelists	10:00 – 10:30

Thank you, California COVID-19 Vaccination Program Providers!

A Moment of Gratitude

Robert Schechter, MD, CDPH

Announcements

Leslie Amani, CDPH

- Work directly with eTrueNorth to enroll your pharmacy location in the Bridge Access Program.
- eTrueNorth makes participation easy by providing a secure online platform for convenient patient sign-up and participating pharmacy reimbursement.
- Interested pharmacies can visit www.joinetruenorth.com to enroll.

To register, visit:
www.joinetruenorth.com

The Bridge Access Program is funded by the U.S. Department of Health and Human Services and the Center for Disease Control and Prevention.

All pharmacy applications are subject to approval by HHS.



CDPH Call Center

September 2023

Old Name: Covid 19 Public Call Center

New name: California Department of Public Health Call Center

Phone: 833.422.4255; M – F 8AM – 5PM (Closed Weekends/Holidays)

Top selections week of 9/18/23

- Vaccine Line
- COVID-19, General
- Treatments
- DVR

CDPH Required Training

IMMUNIZATION BRANCH

COVID–19 Vaccine Training

Training and Resources

- COVID-19 Vaccine Product Training
- Technical Resources for New Vaccinators

Required Training for Participation in the California Bridge Access Program

Providers and key practice staff storing, handling, managing, or administering vaccines must complete the required training to meet federal and state program requirements.

Program Training

This training prepares sites to incorporate program requirements into clinic protocols and identifies key resources for use on the job. Organization & Location Coordinators must complete the required program training in myCAvax during enrollment but may access the lessons below. Review times are approximate.

CDPH Required Training Page

Product trainings for the updated 2023-24 COVID-19 vaccines are now live."

Infodemiology.com

- New resource for clinicians and other health care providers.
- **Infodemiology Brief:** Monthly newsletter with reports on trending health narratives and helpful resources. Sign up.
- **Insights & Dashboards:** Weekly misinformation updates and national and state dashboards with real-time media data.
- **Infodemiology Training Program:** Learn how to identify and respond to trending health narratives. Join the waitlist for the October launch.



Archived COVID-19 Crucial Conversations Webinar

Topic: Talking with Patients about the Updated COVID-19 Vaccine

Description: Learn conversation methodologies for effectively talking with patients about the updated 2023-2024 COVID-19 vaccine.

Speaker: Dr. Alex McDonald, cofounder of #ThisIsOurShot

Link to Slides

Link to Recording

Shot by Shot: Cinthya's Story

Cinthya's Story

COVID-19 | Adult | English

Infographic

Download Infographic

"I would see the tubes there at my bedside and wondered if I would need to be intubated, and if so, would I ever go home again?"

I'm 36 and I've been a registered nurse and the director of a surgi- center in Beverly Hills for about six years. When the pandemic hit 2020, we had to make a lot of changes in the way we did our busin to keep everyone

safe, especially infection control procedures in cleaning and everyo wearing masks. Also, we restricted who could come into the clinic, patients couldn't bring family members with them anymore. We we trying to protect patients, their family members, and us, the clinic s

My Message About COVID-19 and the COVID-19 Vaccine

I'm sharing my story because I want everyone to know how seriously ill COVD-19 made me, a healthy nurse and mom at age 36. It's so contagious and the fact that my mom was just in another room during my home recovery was stressful too. Now that we have the COVID-19 vaccine I hope everyone will get vaccinated as soon as it's available. Thank goodness my story has a happy ending. Too many people who end up in the ICU with COVID-19 don't go home.

Clinic, Chinatown Service Center, Los Angeles



Clinic, Chinatown Service Center, Los Angeles

Riverside County

Lake County

Pop-up clinic events in Lakeport Elementary School



MEDICAL
RESERVE CORPS

COVID-19 Vaccine Poll: Life Events 2020 - Present

What life event changes happened to you and your family during the pandemic?

Choose as many as apply:

- ❑ Change in relationship status
- ❑ New job
- ❑ Welcomed a new baby(ies)
- ❑ Moved
- ❑ Had a family member or friend die
- ❑ Adopted a pet
- ❑ Had a pet die
- ❑ Adopted a new fitness plan
- ❑ Adult child(ren) moved back in
- ❑ Accomplished bucket list item(s)

Potential Impacts:
Federal Government Shutdown

Maria Volk, CDPH

Impacts to Immunization (IZ) Services

- Many CDC staff will be furloughed. If the furlough is extended, would anticipate longer wait times for responses from CDC and could impact the delivery of routine work products.

- CDC staff that work on vaccine ordering and allocations have been exempted, so CDPH does not anticipate any issues with vaccine ordering, delivery, or allocations (for all funding sources).

- CDC Grants that have already been awarded will have no impacts (IZ grants have already been awarded for this FY!)

- Immunization Branch staff will not be impacted (Exception: CDC Public Health Advisors) .



Vaccine Administration Data

Sharon Brummitt, CDPH

COVID-19 DATA

12,541

COVID-19 Vaccine Providers

82%

Of California has received a vaccine

89,825,577

Total Doses Administered since 2020

32,700,544

COVID-19 Vaccine Recipients

42%

65+ Received a Bivalent Booster

AIRA 2023 NATIONAL MEETING
AIRA 2023 NATIONAL MEETING
AIRA 2023 NATIONAL MEETING
AIRA 2023 NATIONAL MEETING
AIRA 2023 NATIONAL MEETING
AIRA 2023 NATIONAL MEETING
AIRA 2023 NATIONAL MEETING

AIRA 2023
NATIONA
Meeting


IF I WAS A JEDI,
THERE'S A 100%
CHANCE I WOULD
USE THE FORCE
INAPPROPRIATELY.

CDPH Immunization Branch (IZB) Conference Attendees

COVID-19 Vaccine Trivia

What was the date of the first COVID-19 vaccine administered in California?

- ❑ December 7, 2020
- ❑ December 14, 2020
- ❑ January 5, 2021
- ❑ January 7, 2021

COVID-19 Vaccine Trivia

What was the date of the first COVID-19 vaccine administered in California?

- ❑ December 7, 2020
- ❑ December 14, 2020
- ❑ January 5, 2021
- ❑ January 7, 2021

Clinical Update

Caterina Liu, MD, CDPH

Calendario de la Vacuna COVID-19 2023-24





Updated COVID-19 Vaccine Timing Guide 2023-2024



COVID-19 Vaccine Timing 2023-24 –Routine Schedule

Age*	Vaccine	If unvaccinated:	If had any prior doses, give 2023-24 doses:
6 months–4 years†	Pfizer–Infant/Toddler	1st Dose → 3-8 weeks** → 2nd Dose → ≥8 weeks → 3rd Dose	If 1 prior dose, then: 3-8** weeks → 1 → ≥8 weeks → 2 If ≥2 prior doses, then: ≥8 weeks → 1
	Moderna–Pediatric≠	1st Dose → 4-8 weeks** → 2nd Dose	If 1 prior dose, then: 1 month → 1 If ≥2 prior doses then: 2 months → 1
5–11 years	Moderna–Pediatric≠	1 Dose	If 1 or more prior doses (of any of the 4 brands), then^: ≥2 months → Updated 2023-24 Formulation Moderna/Pfizer
	Pfizer–Pediatric	1 Dose	
12+ years	Pfizer–Adol/Adult (Comirnaty)	1 Dose	
	Moderna–Adol/Adult (Spikevax)	1 Dose	
	Novavax (2021)	1st Dose → 3-8 weeks** → 2nd Dose 2023-24 formulation coming soon!	

* See CDC recommendations for children transitioning from a younger to older age group
† Children 6 months – 4 years should receive the same brand of the updated vaccine as the prior doses they received.
** An 8-week interval may be preferable for some people, especially for males 12-39 years.
≠ All Moderna doses 6 months – 11 years are 0.25 mL (25 mcg).
^ Janssen (J & J) vaccine has been deauthorized. Follow schedule for 12+ years for any prior doses.

View Interim Clinical Considerations for Use of COVID-19 Vaccines for details. Schedule is subject to change.

California Department of Public Health, Immunization Branch — IMM-1396 (9/14/23) Page 1 of 2



COVID-19 Vaccine Timing 2023-24 if Moderately/Severely Immunocompromised

Age	Vaccine	If unvaccinated:	If had any prior doses give 2023-24 doses:
6 months–4 years	Pfizer Infant/Toddler	1st Dose → 3 weeks → 2nd Dose → ≥8 weeks → 3rd Dose → ≥2 months → Optional Dose*	1 prior dose: 3 w → 1 → ≥8 w → 2 ≥2 prior doses: ≥8 w → 1 → ≥2 m → Optional Dose*
	Moderna–Pediatric	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose*	1 prior dose: 4 w → 1 → ≥4 w → 2 2 prior doses: ≥4 w → 1 ≥3 prior doses: ≥8 w → 1 (for ages 5+ yrs, Pfizer dose is also OK) → ≥2 m → Optional Dose*
5–11 years	Moderna–Pediatric	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* (Moderna/Pfizer)	
	Pfizer–Pediatric	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* (Moderna/Pfizer)	1 prior dose: 3 w → 1 → ≥4 w → 2 2 prior doses: ≥4 w → 1 ≥3 prior doses**: ≥8 w → 1 → ≥2 m → Optional Dose* (Moderna/Pfizer)
12+ years	Pfizer–Adol/Adult (Comirnaty)	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* (Moderna/Pfizer)	
	Moderna–Adol/Adult (Spikevax)	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* (Moderna/Pfizer)	1 prior dose: 4 w → 1 → ≥4 w → 2 2 prior doses: ≥4 w → 1 ≥3 prior doses**: ≥8 w → 1 → ≥2 m → Optional Dose* (Moderna/Pfizer)
	Novavax (2021)	2023-24 formulation coming soon! 1st Dose → 3 weeks → 2nd Dose	If 1 or more prior doses, then: ≥8 weeks → Updated 2023-24 Formulation Moderna/Pfizer → ≥2 m → Optional Dose* (Moderna/Pfizer)

* An **optional dose** may be given ≥2 months after the last dose. **Further doses** may be given at the healthcare provider's discretion. See Table 2 for vial and dosage.
** Ages 5+ years may be given Moderna or Pfizer after ≥3 prior doses.

California Department of Public Health, Immunization Branch — IMM-1396 (9/20/23) Page 2 of 2

COVID-19 Vaccine Product Guide - Updated

COVID-19 Vaccine Product Guide

Check vaccine labels and FDA materials before use to avoid mix-ups.
EUA fact sheets supersede info on vials and carton. Refer to CDC Product Guide for more information.

	Pfizer		
	Infant/Toddler 6 months–4 years	Pediatric 5-11 years	Comirnaty 12+ years
	2023-24 Formula	2023-24 Formula	2023-24 Formula
Packaging	Yellow Cap	Blue Cap	Gray Cap
Doses Per Vial	3 doses	1 dose	1 dose
Carton Size	30 doses	10 doses	10 doses
NDC-Unit of Use (vial)	59267-4315-01	59267-4331-01	00069-2362-10
CVX Code	302	301	300
CPT Code	91318	91319	91320
Program Availability	VFC	VFC	VFC, BAP
Min. Standard Order*	30 doses	10 doses	10 doses
Storage Limits Before Puncture: Label vaccine with expiration and use-by dates.			
ULT	Until expiration date at -90ºC to -60ºC (-130ºF to -76ºF)		
Thermal Shipper	🚫		
Freezer	🚫		
Refrigerator	Up to 10 weeks at 2º to 8ºC (36°F to 46°F). Write the date on carton–not to exceed expiration.		
Expiration Date	Check the label or Pfizer product website.		
Administration			
Diluent (supplied)	1.1 mL per vial	Do not dilute	Do not dilute
Dose Volume & Dose	0.3 mL 3 mcg dose	0.3 mL 10 mcg dose	0.3 mL 30 mcg dose
Refrigerator Thaw Time (Do not refreeze)	2 hours in carton (2º to 8ºC/36°F to 46°F)		
Room Temp Thaw Time (Do not refreeze)	Vial: 30 minutes at up to 25°C (77°F)		
Total Time at Room Temp	Up to 12 hours (including thaw time) at 8ºC to 25ºC (46ºF to 77ºF)		
Storage Limits After Puncture (Mult-dose vials): Record puncture and use-by time on vial label.			
Use-By Limit (Discard Time After 1st Puncture)	Discard 12 hours after dilution. Keep at 2°C to 25°C (35°F to 77°F)	N/A	N/A

* Orders for privately purchased vaccines may have different order minimums.

COVID-19 Vaccine Product Guide

Check vaccine labels and FDA materials before use to avoid mix-ups.
EUA fact sheets supersede info on vials and carton. Refer to CDC Product Guide for more information.

	Moderna			Novavax
	Pediatric 6 months–11 years	Spikevax 12+ years	Spikevax 12+ years	Adol/Adult 12+ years
	Green label 2023-24 Product	Blue label 2023-24 Product	2023-24 Product	2021 Product (new product coming soon)
Packaging	Dark Blue Cap	Dark Blue Cap	Syringe	Royal Blue Cap
Doses Per Vial	1 dose	1 dose	1 dose	5 doses
Carton Size	10 doses	10 doses	10 doses	50 doses
NDC-Unit of Use (vial)	80777-0287-07	80777-0102-04	80777-0102-01	80631-0102-01
CVX Code	311	312	312	211
CPT Code	91321	91322	91322	91304
Program Availability	VFC	VFC, BAP	TBD	TBD
Min. Standard Order*	10 doses	10 doses	TBD	TBD
Storage Limits Before Puncture: Label vaccine with expiration and use-by dates.				
ULT	🚫			🚫
Thermal Shipper	🚫			🚫
Freezer	Until expiration at -50ºC to -15ºC (-58ºF to 5ºF)			🚫
Refrigerator	Up to 30 days (not to exceed expiration date) at 2–8ºC (36-46ºF)			Until expiration
Expiration Date	Check Moderna product website or QR code.			Check product website.
Administration				
Diluent (supplied)	Do not dilute			Do not dilute
Dose Volume & Dose	0.25 mL 25 mcg	0.5 mL 50mcg	0.5 mL 50mcg	0.5 mL 5 mcg
Refrigerator Thaw Time (Do not refreeze)	45 minutes for single dose vial or 1 hour for syringe at 2°C to 8°C (36°F to 46°F). Let stand at room temp for 15 min before administering.			N/A
Room Temp Thaw Time (Do not refreeze)	15 minutes for single dose vial or 45 minutes for syringe at 15º to 25ºC (59º to 77ºF)			N/A
Total Time at Room Temp	Store up to 24 hours at 8°C to 25°C (46°F to 77°F)			N/A
Storage Limits After Puncture (Mult-dose vials) Record use-by time on vial.				
Use-By Limit (Discard Time After 1st Puncture)	N/A. Discard after single use.			Discard 12 hours after puncture. Keep at 2° to 25°C (36° to 77°F)

* Orders for privately purchased vaccines may have different order minimums.

COVID-19 Vaccine Product Guide

Do Not Use Deauthorized Products:

Use only COVID-19 vaccine products updated for 2023-24.

Vaccine Product Fact Sheets Updated in BAP POM



Receiving & Storing Vaccines

Moderna Spikevax Vaccine 12Y+ Fact Sheet

Approval of Spikevax (COVID-19 Vaccine, mRNA) to include the 2023-2024 formula, a change to a single dose for individuals 18Y+ and approval of a single dose for individuals 12-17Y. Updated to include a monovalent (single) component that corresponds to the Omicron variant XBB.1.5.

Product Profile: NDC 80777-0102-04 Provider Letter | Package Insert

- Vaccine ships frozen between -50°C and -15°C (-58°F and 5°F). For receiving, see How to Receive Moderna Vaccines.
- Ships as 10-pack carton, single-dose vials (minimum 10 doses).
- Storage & handling requirements remain the same as for bivalent.
- Store unpunctured vials in a freezer at -50°C to -15°C (-58°F to 5°F) **until expiration** or refrigerator at 2°C to 8°C (36°F to 46°F) for up to **30 days** or hold at 8°C to 25°C (46°F to 77°F) for up to **24 hours** before puncture.
- Organize storage units to reduce administration errors; group products by age and label cartons, baskets, or shelf space in large letters.
- Apply storage and beyond-use date tracking labels (TBD) to prevent administration errors.
- Look for blue age-indicator label & Spikevax. Read label carefully; don't rely on cap color.
- Spikevax was previously approved as a two-dose series for individuals 18 years of age and older.
- Dosing volume: 0.5 mL (50 mcg). DO NOT DILUTE.
- Expiration date: Scan QR code on carton or expiry checker (TBD).
- Use-by limit: Discard after single use.
- **Do not use vaccine after earliest expiration or beyond-use date.**
- FDA page | Moderna at a Glance | Standing Orders | CDC Resources

9/28/23

[Moderna Spikevax Vaccine 12Y+ Fact Sheet]



Receiving & Storing Vaccines

Pfizer-BioNTech Comirnaty Vaccine 12Y+ Fact Sheet

Approval of Comirnaty (COVID-19 Vaccine, mRNA) to include 2023-2024 formula, and a change to a single dose for individuals 12Y+. Updated to include a monovalent (single) component that corresponds to the Omicron variant XBB.1.5. **DO NOT DILUTE.**

Product Profile: NDC 00069-2362-10 Provider Letter | Package Inserts

- Vaccines ship from the manufacturer with dry ice and between -90°C and -60°C (-130°F to -76°F); ensure staff are trained on dry ice safety.
- Ships as 10-pack carton, single-dose vials (minimum 10 doses).
- For receiving, see How to Receive Pfizer-BioNTech Vaccines or this video.
- Storage & handling requirements remain the same as for bivalent.
- Store unpunctured vials in ULT unit (-90 to -60°C) **until expiration** or refrigerator at 2-8°C (36-46°F) for up to **10 weeks** or at 8°C to 25°C (46°F to 77°F) for up to **12 hours** before puncture. **DON'T FREEZE.**
- Organize storage units to reduce administration errors; group products by age and label cartons, baskets, or shelf space in large letters.
- Apply storage and beyond-use date tracking labels (TBD) to prevent administration errors.
- Read label carefully; don't rely on cap color.
- Comirnaty was previously approved as a two-dose series for individuals 12 years of age and older.
- Dosing volume: 0.3 mL (30 mcg). DO NOT DILUTE.
- Expiration date: Scan QR code on carton or expiry checker (TBD).
- Use-by limit: Discard after single use.
- **Do not use vaccine after earliest expiration or beyond-use date.**
- FDA page | Pfizer at a Glance | Standing Orders | CDC Resources

9/28/23

[Pfizer-BioNTech Comirnaty Vaccine 12Y+ Fact Sheet]

[U.S. COVID-19 Vaccine Product Information]

Additional COVID-19 Resources

CDC COVID-19 Vaccine Product Information Page

- Updated Standing Orders
- Updated product job aids

CDC Vaccine Information Statements Page

- There is not yet a COVID-19 Vaccine Information Statement (VIS).
- Until a VIS is available for approved COVID-19 vaccines, a provider may use the manufacturer's package insert or produce their own information materials to inform patients about the benefits and risks of that vaccine.
- Links to FDA materials available at EZIZ



Coadministration of COVID-19 Vaccine and Other Vaccines

In accordance with General Best Practice Guidelines for Immunization, routine administration of all age-appropriate doses of vaccines simultaneously (coadministration) is recommended for children, adolescents, and adults if there are no contraindications at the time of the healthcare visit.

Providers may simultaneously administer COVID-19, influenza, and respiratory syncytial virus (RSV) vaccines to eligible patients.



COVID-19 Vaccine Coadministration Tips

Protect yourself from COVID-19, Flu and RSV

CDC Respiratory Viruses page

www.cdc.gov/respiratory-viruses/index.htm

- CDC recommends that everyone 6 months and older stay up to date on COVID-19 vaccines and receive a seasonal flu vaccine.
- If you are 60 years and older, talk to your healthcare provider to see if RSV vaccination is right for you.
- CDC recommends RSV vaccine during 32 through 36 weeks of pregnancy to prevent RSV in infants.
- CDC also recommends nirsevimab for all infants younger than 8 months who are born during or entering their first RSV season, as well as older babies 8 to 19 months old including American Indian or Alaska Native (AIAN) children.



Recording Doses

Electronic Records – options include

- Digital Vaccine Record
- California Immunization Registry (CAIR)
- Electronic Health Record (EHR) systems



Paper Records

- CDC record cards may continue to be used if helpful, but are no longer mandatory
  - Please shred unneeded cards
- Other formats may be used as well



[Digital Vaccine Record (DVR) portal]

Digital Vaccine Record



DVR Fact Sheet



Spanish Version

- To access their DVR, patients should visit the Digital Vaccine Record (DVR) portal (myvaccinerecord.cdph.ca.gov)
- Flyers are also available in Arabic, Simplified Chinese and Traditional Chinese, Korean, Tagalog and Vietnamese.
- The DVR request form is also available in the languages listed above to support easy communication. Records are also printable in these languages! See our DVR FAQs for more information.

COVID-19 Vaccine Trivia

Who received the first dose of COVID-19 vaccine in California?

- ❑ Governor Gavin Newsom
- ❑ Helen Cordova, ICU Nurse
- ❑ Dr. Tomás Aragón
- ❑ Amy Pine, CDPH

COVID-19 Vaccine Trivia

Who received the first dose of COVID-19 vaccine in California?

- ❑ Governor Gavin Newsom
- ☑ Helen Cordova, ICU Nurse
- ❑ Dr. Tomás Aragón
- ❑ Amy Pine, CDPH

"I'm excited. I'm hopeful," she said. "I really encourage everyone to consider receiving the vaccine so we can start putting an end to this pandemic."

Helen Cordova, an intensive-care nurse at Kaiser Permanente in Los Angeles, was the first person to get the vaccine in California.

Thank you to California's Public Health Medical Officers for your tireless support!

Facility Administrators of National Renal Care volunteered at the mass COVID-19 vaccination held at Magic Mountain in January 2021

Butte County Public Health Volunteers at Clinic Day 1: Silver Dollar Fairgrounds, Chico, CA

Butte County Public Health's Rosie, Andrea, and Erin at Downtown Chico's Farmers' Market

Butte County Public Health's "Dia de los Muertos" table

Butte County Mobile Medical Unit at Biggs, CA Parade
Photos Courtesy of Stephanie Patterson Butte County Public Health

COVID-19 Vaccine Access

Claudia Aguiluz, CDPH

Vaccine and Clinic Eligibility Guidelines by Funding Source, continued

Program	Vaccines for Children Program (VFC)	Bridge Access Program (BAP)	317 Local Health Dept.	Vaccines for Adults Program (VFA)	State General Funds (SGF)
Vaccines	• COVID-19 • DTaP • Hepatitis A • Hepatitis B • Hib • HPV • Influenza • Meningococcal Conjugate (MenACWY) • Meningococcal B (MenB) • MMR • Pneumococcal Conjugate (PCV15 and PCV20) • Pneumococcal Polysaccharide (PPSV23) • Polio (IPV) • Rotavirus • RSV (coming soon) • Td, Tdap • Varicella	• COVID-19	• Hepatitis A • Hepatitis B[3] • HPV • Meningococcal Conjugate (MenACWY) • MMR • Pneumococcal Conjugate (PCV20) • Td only when Tdap is not indicated[4] • Tdap • Varicella • Zoster	• Hepatitis A • Hepatitis B • HPV • Meningococcal Conjugate (MenACWY) • MMR • Pneumococcal Conjugate (PCV20) • Td only when Tdap is not indicated • Tdap • Varicella • Zoster	• Influenza • Tdap (children only)
Ordering Website	myVFCVACCINES	myCAvax California Vaccine Management System	myVFCVACCINES	myVFCVACCINES	myCAvax California Vaccine Management System for flu vaccine (refer to your LHD for other vaccines)

1. Fully insured children and adults are not eligible to receive 317 vaccine routinely (adults enrolled in Medi-Cal/Medi-Cal managed care plans are considered fully insured). 317 vaccine may not be used in travel clinic settings.
2. Depending on funding, State General Fund vaccines may vary.
3. Adults with Medicare Part B (without Part D) are eligible if they are at low-risk for Hepatitis B. See VFA Eligibility Based on Insurance Status (EZIZ.org/assets/docs/IMM-1247.pdf) for more details.
4. Adults with Medicare Part B (without Part D) are eligible if they are receiving Td as a routine vaccine (i.e., do not have a wound). See VFA Eligibility Based on Insurance Status (EZIZ.org/assets/docs/IMM-1247.pdf) for more details.

Vaccine and Clinic Eligibility Guidelines by Funding Source

For Health Departments and CDPH Approved Health Department Authorized Sites (Effective 10/01/2023 through 9/30/2024)

Program	VFC Vaccines for Children Program	BAP Bridge Access Program	317 Local Health Departments[1]	VFA Vaccines for Adults Program	SGF State General Funds[2]
Funding	VFC-Federal entitlement program for eligible children. Funds are used to pay for vaccines recommended by ACIP and approved into the VFC program.	BAP-Limited federal funds (Section 317) for eligible adult populations to maintain access to COVID-19 vaccines through existing public health infrastructure.	317-Limited federal funds (Section 317) used to pay for adult vaccines recommended by ACIP and support limited vaccine supply for outbreak activities via Public Health Departments.	317-Limited federal funds (Section 317) used to pay for adult vaccines recommended by ACIP and included in the VFA Program.	Limited state funds for the purchase of vaccines to prevent respiratory illness.
Age and Eligibility	Children Birth–18 years: • Medi-Cal/CHDP eligible • Uninsured (no health insurance) • American Indian or Alaskan Native • Underinsured: health insurance does not cover vaccines (ONLY if the LHD has a FQHC or RHC designation).	Adults 19 years and older: • Uninsured (no health insurance) • Underinsured (vaccines are not covered by insurance)	Adults 19 years and older: • Uninsured adults (no health insurance) • Underinsured adults (vaccines are not covered by insurance) • Insured exceptions-Adults part of outbreak control, post-exposure prophylaxis, or disaster relief efforts as approved by CDPH & LHDs. • Household contacts or sexual contacts of HBsAg+ pregnant woman	Adults 19 years and older: • Uninsured adults (no health insurance) • Underinsured adults (vaccines are not covered by insurance)	All ages: • No restrictions
Clinic Type	• Federally Qualified Health Center (FQHC), Rural Health Center (RHC), and State-licensed • Community Health Centers • Health Department and CDPH Approved Health Department Authorized Sites • Juvenile halls/youth correctional facilities • Private providers, School-based clinic, Hospitals, Pharmacies (pilot program)	• Health Department Clinics • Federally Qualified Health Center (FQHC), Rural Health Center (RHC) • Tribal Clinics • Indian Health Services • Limited sites designated by Local Health Department as BAP Provider	• Health Department and CDPH Approved Health Department Authorized Sites (HDAS) • Juvenile halls/youth correctional facilities (for 19-25 years of age)	• VFC enrolled Federally Qualified Health Center (FQHC), Rural Health Center (RHC)	• State-licensed Community Health Centers • Federally Qualified Health Center (FQHC), Rural Health Center (RHC) • Health Department and CDPH Approved Health Department Authorized Sites (HDAS) • Private provider • School-based clinic

CDPH Eligibility Guidance

COVID-19 Vaccine Access post Commercialization

Adult populations:

- **CA Bridge Access Program** (BAP) for uninsured/under insured adults.
  - 584 Active BAP Providers
  - 580 Pending BAP Program enrollment
- **Bridge Access Program for Retail Pharmacies** have begun supporting adult uninsured/underinsured vaccination through select enrolled pharmacies.
- **Healthcare providers** are in process of making vaccines available for insured adults, as they work with private suppliers, redistributors, and manufacturers on acquiring private supply.

COVID-19 vaccines are still available at no cost to most people through their private health insurance, Medicare, and Medicaid plans.



Overview CDC's Bridge Access Program (cdc.gov)

COVID-19 Vaccine Access post Commercialization

Pediatric populations:

- Vaccines are now available through the **Vaccines for Children (VFC) Program** for eligible children under 19 years of age.
  - COVID-19 vaccines are now part of the VFC Order Form available for routine vaccine ordering by over 3,500 active CA VFC Providers

- **Healthcare providers** are in process of making vaccines available for insured pediatric populations, as they work with private suppliers, redistributors, and manufacturers on acquiring private supply.

COVID-19 vaccines are still available at no cost to most people through their private health insurance.

Vaccines For Children Program Eligibility

Michelle Meszaros, IZ Coordinator, and Jennifer Phan, Former Vaccine Branch Director, sneaking a peek at our first shipment of COVID-19 vaccine.

Deputy Health Officer, Dr. David Ghilarducci providing vaccines at a community pop-up at the Museum of Art in Santa Cruz.



Santa Cruz County Health Officer, Dr. Gail Newel, providing a COVID-19 Vaccine at t
Cruz County Fairgrounds Mass Vaccination efforts in early 2021.

Mass Vax – Bunny Ears – Assistant Director, Public Health Manager, and Communications Officer, celebrating with Dr. Fauci at our closing of mass vaccination efforts, and celebrating our local community.

Santa Cruz County: Watsonville Vaccine Center Crew – CDPH Staff Nurses, Local Medical Reserve Corps Volunteers, and members of the Public Health Team, at the staff recognition event near the closing of our Watsonville Vaccine Center (provided over 9K vaccines in 7 mos.).



Santa Cruz County: First week of mass vaccination efforts-3 days of rain downpours, shifting plans, and administering vaccines to community members.

Wee Kirk – A local church in Ben Lomond, CA where Public Health and one of our local FQHC partnered for a targeted weekend clinic.

Local Medical Reserve Corps and Public Health staff celebrating our local community at the end of our mass vaccination efforts.



La Familia Mobile a Familia Mobile team through the Pandemic. This team has been everywhere testing, vaccinating and breaking through the language barriers to provide services to all the diverse communities within Alameda County. They contributed to the overall success and continue to do so and stay committed to continuous healthcare!

Storage and Handling with Kate and Al

Katherine McHugh and Alan Hendrickson, CDPH

Pfizer Diluent

- Pfizer vaccine for ages 6mo-4 years requires diluent: 1.1mL of normal saline
- Pfizer vaccine for ages 6mo-4 years supplied by the government will come with diluent!
- The diluent should arrive before the vaccine. If you do not receive the diluent by the time you receive the vaccine, you should report this as a shipping incident
- Do NOT use diluent from other vaccines (MMR, etc., for example) for the Pfizer vaccine. Use **only** the diluent supplied for the vaccine with which it was supplied with!

myCAvax Waste Reporting Close-out Timeline

TODAY!

Final!
Saturday
9.30.23

Waste Reporting Deadline:
September 30, 2023
11:59PM

"Starting strong is good. Finishing strong is epic!"

Robin Sharma

"The flight ain't over until the paperwork is complete!"

Anonymous

Napa County Public health Team during our Covid outreach (from testing to vaccinating)

Napa County Public health Team during our Covid outreach (from testing to vaccinating)



Napa County Public health Team during our Covid outreach (from testing to vaccinating)

FIGHT
Trojans

MedEx
PHARMACIES
COVID-19
VACCINATION
818.925.1321
8441
FOOTHILL BL
SUNLAND, CA
91040

MedEx
PHARMACIES
COVID-19
VACCINATION
818.925.132
8441
FOOTHILL BL
SUNLAND, CA
91040

Blanca Corona distributing PPE to FQHCs in Solano/Contra Costa Counties.

Vaccine Management

Josh Pocus, My Turn, and Claudia Aguiluz, myCAvax

What's New in My Turn? – Release 43

New updates for My Turn Public and Clinic launched on **Wednesday, September 20, 2023**!

My Turn Public

Release Highlights

When scheduling vaccine appointments, patients **are able to view:**

- ✓ A filter on the clinics that serve either insured or uninsured / under-insured patients based on the health insurance question
- ✓ The clinic phone number in the 'Clinic Details' section
- ✓ An updated description on the clinic card that says "Please contact the clinic to confirm the patient's insurance is accepted"

When scheduling vaccine appointments, patients **are no longer be able to view:**

- ✓ The 'Yes, but cannot provide information' option on the health insurance question

My Turn Clinic

Release Highlights

Clinic Managers and Vaccine Administrators **are able to**:

- ✓ Add multiple funding sources to a single vaccine inventory
- ✓ Select / update funding source on the Walk-in, IIS Edit, Inline / Bulk Upload, and Vaccine Administration flows
- ✓ Select vaccine supply for publicly or privately funded vaccines on clinic setup and clinic vaccine supply pages
- ✓ View / download new reports that include vaccine funding source and patient insurance information for billing purposes
- ✓ Add privately purchased vaccines to the clinic inventory

Updated My Turn Dashboard: View Appointments by Funding Source

Clinic Managers can now view a new tile on the My Turn Clinic dashboard that displays details about appointments completed through various funding sources.



What to Expect: My Turn and COVID-19 Vaccine Updates



***NOTE**: Vaccine supply is now distinguished by insurance status and will impact public clinic tags and scheduling.

What's New in myCAvax? – Release 43

New updates for Providers launched on **Friday, September 22, 2023!**

Providers

Release Highlights

Providers can:

Shipment Incident

- ✓ See updated fields on the 'New Shipment Incident' pop-up window

Provider Community Site

- ✓ See an updated landing page displaying program tiles based on the Provider's program enrollment permissions
- ✓ See the 'Program Selected' dropdown on multiple pages based on the Provider's program enrollment permissions
- ✓ See orders on the 'Vaccine Orders' page based on the program selected from the 'Program Selected' dropdown
- ✓ See the COVID-19 or SGF 'Shipment Incidents' page based on the program selected from the 'Program Selected' dropdown
- ✓ See the COVID-19 or SGF 'Dashboard' page based on the program selected from the 'Program Selected' dropdown
- ✓ No longer see the 'Open Transfer Orders' pop-up window on the landing page

Vaccine Ordering – Provider

- ✓ See the COVID-19 or SGF 'Vaccine Order Request' page based on the program selected from the 'Program Selected' dropdown
- ✓ Be able to place vaccine order requests for SGF flu vaccine on the 'State General Fund - Vaccine Order Request' page
- ✓ Receive email notifications when their vaccine order request has been rejected or progressed to 'Fulfillment Pending'
- ✓ Receive a reminder email for an expiring COVID-19 or Outbreak draft order four days after the order creation date
- ✓ Have their draft orders deleted seven days after the order creation date; they will also receive a confirmation email for the same
- ✓ Be directed to the appropriate 'Vaccine Order Request' page when they click the 'Submit Order' button on a draft order

Location Account

- ✓ Have their location account's sub-status updated to 'On-Hold' and the 'Reason for On-Hold' field updated with the 'Provider Account Changes' value when the shipping address fields are updated

Personalized myCAvax Home Page

Providers participating in multiple programs will see a new multi-program home page while logging in to the Provider Community.

Providers participating in only one program will only see the program-specific home page while logging in to the Provider Community.





State General Fund Flu Vaccine Supply Update

- Additional doses of **Fluarix** (adult intention) will be added to allocations this week
- **FluBlok** will **NOT** be available this season (Sanofi does not plan to bring any more doses to the market)
- **Fluad** is the replacement product for FluBlok:
  - Preferential vaccine for 65+
  - Licensed 65+
  - LHD allocations will remain the same as FluBlok
  - Doses expected to arrive during the week of Sept 25 (full order)

Bridge Access Program: Eligibility Refresher



As a reminder, Providers serving uninsured / underinsured adults through Public Health Departments, Federally Qualified Health Centers (FQHCs) / Rural Health Centers, Tribal Clinics, and Indian Health Services sites are eligible for the Bridge Access Program (BAP).

Additional Providers deemed eligible by LHDs may also be able to enroll in BAP.

Suggesting a Provider for BAP enrollment?
Contact the Provider Call Center for support at providercallcenter@cdph.ca.gov or by calling (833) 502-1245, M-F from 8:00 AM to 5:00 PM PT.

Bridge Access Program: Vaccine Reporting

As a reminder, Bridge Access Program (BAP) Providers are required to report doses administered (including eligibility category of 317) using My Turn or their EHR connected to CAIR.



For more information, please review the BAP Provider Operations Manual and the BAP Requirements at a Glance document.

Bridge Access Program: Allocation and Ordering Update

BAP vaccine ordering was made available to Providers on **Monday, September 18, 2023**. Providers may expect additional ordering updates from CDPH via email.

To prepare to order, Providers must:

- Complete required training*
- Enroll their location in BAP in myCAvax
- Upload their signed Provider Agreement in myCAvax

***NOTE**: Required CDC product training has not been released. For now, review vaccine fact sheets.

Bridge Access Program: Enrollment Update

To enroll in the Bridge Access Program, your Organization Vaccine Coordinator and / or Primary Vaccine Coordinator can complete the following steps:

1. Log in to myCAvax.
2. Complete the required BAP training from the 'Training' tab in myCAvax.
3. Select your COVID-19 program location from the pop-up window that appears on the home page.
4. Provide the required information and upload a copy of the signed BAP Provider Agreement.
5. Click the 'Submit' button and your COVID-19 location will be placed in the 'Active' status.

NOTE: If you have multiple locations eligible to participate in the Bridge Access Program, you will need to enroll each location individually.

For more information, please see the new Enrolling in the Bridge Access Program deck.

Slide Icon Key

Icon	Meaning
	This is to label slides that are referencing upcoming or existing functionality and how to use it in the system.
	This is to label slides that include important system reminders.
	This is to label slides that include tips and best practices to improve your system experience.

myCAvax – Known Issues – *Updated 9/21*

Known Issues

‘Physician’s Assistant’ License Type on SGF Enrollment Leading to Endless Spinner

- ✓ For LHD users still completing their State General Fund enrollment, if you add a Provider of Record with a license type of ‘Physician’s Assistant,’ you will be met with an endless spinner when trying to complete the enrollment.

Workaround / Next Steps

- ✓ Estimated Fix: TBD
- ✓ Workaround: Please use the 'Other' license type instead of ‘Physician’s Assistant’ and leave a chatter note on the ‘Program Location Application’ record to let the enrollment team know that your Provider of Record is a ‘Physician’s Assistant.’

Parking Lot


Lee, Mai Li
Gebert, Matt
DeKleer, Kristal@CDPH
MyTurn.ca.gov
Joshua Pocus
DPH
licHealth
Pine, Amy@CDPH

Thank You: My Turn and myCAvax Monday Office Hours Team

And thank you, My Turn Mary!

CDPH hosted the first My Turn and myCAvax Monday Office Hours Webinar on **Monday, March 8, 2021.** Since then, we've hosted 87 sessions reaching 8,624 total attendees.

CDPH is grateful for your partnership and commitment to excellence.



Historical Timeline

Remember these names?
COVIDReadi
PrepMod
Interim CalVax

2020

January 2021
My Turn Clinic
My Turn Public

February 2021
CalVax > **myCAvax**

March 2021
Monday My Turn myCAvax Office Hours

2022

2023
Final Session September 18, 2023

COVID-19 Vaccine Quality Assurance

Eugene Beronilla and Francisco Borboa, CDPH

2021-23 COVID VACCINE QA UPDATE: REGIONS, DELIVERABLES, & PROGRESS

1222
VISITS

- **HRSA Subset**: 267
- **IHS Subset**: 8
- **OTHER PROVIDERS**: 947
- **DEPOTS**: 189

- **BY CDPH**: 546
- **BY LHJs**: 676
- **IN-PERSON**: 722
- **VIRTUAL**: 500



100%
COUNTIES

Data as of September 21, 2023

COVID VACCINE QA TIPS: TOP FIVE NONCOMPLIANT AREAS IDENTIFIED DURING QA VISITS



Data as of September 21, 2023

1. Report vaccine administration errors to VAERS & IIS
   Steps to follow in the event of error POM page 118
2. Report ancillary supply kit defects to all entities as applicable Reporting shipment incidents POM page 82-83
3. Use qualified containers/pack outs to transport vaccine
   Transporting Vaccine POM pages 101-102
4. Monitor and report temperature excursions
   Document and Report all temperature excursions POM pages 89-91
5. Document unused, spoiled, expired, or wasted vaccine
   Reporting & Disposal of Nonviable Doses POM pages 97-98

Beyond Use Date (BUD)

The beyond use date, or BUD, is the last date or time that a vaccine can be safely used after it has been moved from one storage state to another (e.g., frozen to refrigerated) or prepared for patient use.

- The BUD replaces but does not extend the manufacturer expiration
- If vaccine has no beyond use date, use the expiration date
- Providers can use BUD storage labels to prevent vaccine administration past beyond use date or create a process to track BUDs

COVID VACCINE QA TIPS: BEYOND USE DATES



COVID-19 Vaccine Product Guide

Use By Date

After first puncture, multidose vials have a shortened use-by-date/time; vial must be labeled with puncture date/time

- When evaluating storage units if punctured vials are present, check for use by date label or process used to track use by date.
- If vaccine has no beyond use date, use the expiration date
- Providers can use BUD storage labels to prevent vaccine administration past beyond use date or create a process to track BUDs

COVID VACCINE QA TIPS: USE BY DATE

Vaccine	Vials Drawn	Initial Puncture	Use By Time	Doses Drawn
Pfizer Baby 6 mo - 4 yrs (0.2 mL)				
Pfizer Baby Bivalent 6 mo - 4 yrs (0.2 mL)				
Pfizer Peds 5 yrs - 11 yrs (0.2 mL)				
Pfizer Peds Bivalent 5 yrs - 11 yrs (0.2 mL)				
Pfizer Adolescent/Adult 12 yrs and up (0.3 mL)				
Pfizer Bivalent 12 yrs and up (0.3 mL)				
Moderna Baby 6 mo - 5 yrs (0.25 mL)				
Moderna Baby Bivalent 6 mo - 5 yrs (0.2 mL)				
Moderna Peds 6 yrs - 11 yrs (0.5 mL)				
Moderna Peds Bivalent 6 yrs - 11 yrs (0.25 mL)				
Moderna Adolescent/Adult 12 yrs and up (0.5 mL)				
Moderna Bivalent 12 yrs and up (0.5 mL)	1	9:37am	9:37p	//

-YOU DROW!





COVID VACCINE QA TIPS: POSITIONING Digital Data Logger (DDL) PROBES

We Could Not Have Done Without **All 61!**

QA Site Visit at Valley Health Team:
Kelley Leung, Kasey Sumeriski, Francisco Borboa

Blanca Brosig and Kelley Leung at CIC Conference



QA Site Visit with AmeriSource Bergen: Kelley Leung and Blanca Brosig

QA Site Visit with Sierra View Medical Center: Kasey Sumeriski & Kelley Leung

QA Reviewer Team (Top row: Mary Vilgera-Wilson, Paola Diaz, Esmeralda Munoz, Blanca Brosig; Bottom row: Kelsey Florio, Michele Cheatham, Kelley Leung, Kasey Sumeriski)

BEING A
PUBLIC
HEALTH
WORKER
IS EASY. IT'S LIKE
RIDING A BIKE
EXCEPT THE BIKE IS ON FIRE
YOU'RE ON FIRE
EVERYTHING'S ON FIRE

Alpine Valley

Mono County

Orange County

Mendocino County

LA County PH and Pharmacy Partner, Cosmed, Pacoima Neighborhood Clinic. All photos courtesy of Laurel Fowler



LA County Pacoima Neighborhood Clinic

Sacramento: Midtown Farmer's Market Pop-up Clinic Promotion

ACPHD at Fremont High School in Oakland

COVID-19 Testing and Therapeutics

Jessica deJarnette, MD, CDPH

At-Home Test Eligibility and Ordering Criteria

- **CDPH is continuing to support organizations that serve the uninsured/underinsured, those with poor access to medical care, and those that are immunocompromised or over the age of 65.**
- LHDs should have received an email on September 8, 2023, advising that local health jurisdictions are eligible to request as many tests needed to support these organizations in their counties.
- **Over the next few months, the State is planning to transition from direct distribution of COVID-19 tests (for example directly to organizations/schools) to distribution solely to the LHJs by December 1, 2023.**
- **We encourage LHJs to order tests as needed and work on local test distribution plans**. CDPH is happy to work with LHJs on their plans and provide contact information of organizations in your jurisdiction that have been directly ordering from the state.

At-Home Test Eligibility and Ordering Criteria

- Organizations eligible to directly request At-home tests include:
  - **Skilled Nursing Facilities and Long-Term Care Facilities:**
    - At-home tests for up to 16-week need to support residents, staff, and visitors with symptoms.
  - **Community Based Organizations:**
    - At-home tests for up to a 16-week need to support the uninsured/underinsured populations, those that have poor access to medical care, and those populations that are high risk. Populations that have Medicare B- as Medicare B does not cover at-home COVID-19 tests.
  - **K-12 Organizations:**
    - At-home tests for the fall semester, up to a 16-week, for K-12 schools, foster care, and before and after school programs.
    - Tests should be requested to support the uninsured/underinsured student populations.
    - Deadline to order for fall semester is October 31, 2023.

At-Home Test Eligibility and Ordering Criteria

- **Early Childhood Education Programs:**
  - At-home tests can be requested for uninsured/underinsured students and staff only.
  - This is a one-time order request. Can request 8 tests per uninsured/underinsured person.
  - Deadline to order is October 31, 2023.
- **Community College Health Centers:**
  - At-home tests can be requested for uninsured/underinsured students only.
  - This is a one-time order request. Can request 8 tests per uninsured/underinsured person.
  - Deadline to order is October 31, 2023.

Questions? Please email **OTCtesting@cdph.ca.gov**

COVID-19 Test to Treat Reminders

TESTING

- COVID-19 antigen tests continue to work on new variants
- For symptomatic people that test negative, recommend repeat testing at 24-48 hours
- Many over-the-counter tests have extended expirations by the FDA

TREATMENT

- Oral antivirals remain very effective against all circulating variants, free to patients, and are in ample supply
- Patients should be evaluated for treatment regardless of vaccination or booster status
- There are many ways patients can access treatment if they are unable to see their healthcare provider
- Positive test not required for treatment

Skilled Nursing Facility Populations

Improve Therapeutic Access in Congregate Health Settings

- Skilled Nursing Facilities and congregate living settings have the best opportunity to test and prescribe within 5 days of symptoms.
- **Despite their high risk, only 1 in 4 nursing home residents with COVID-19 had been treated with evidence-based antiviral treatments by the end of 2022.**
- During the study period, there were 763,340 resident cases of COVID-19 and 136,066 residents treated for COVID-19 among 15,092 nursing homes, equating to an overall oral antiviral or monoclonal antibody treatment rate of 17.8% (95% CI, 17.4%-18.3%).
- By the end of 2022, 41.0% of facilities still had not reported any use.

LTC Residents and Severe Risk for COVID-19

- Paxlovid and other COVID Tx are recommended for people with “risk of progressing to severe COVID-19”
- LTC facility residents, by definition, almost always fall in severe risk category
- Risk factors include older age, medical conditions, or being immunosuppressed
- Note that even when vaccinated and/or boosted, LTC residents are generally on higher end of risk continuum for other risk categories



IDSA Immunocompromised Populations

CDC Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals

SNF and LTCF Surge Readiness

Prepare Congregate Health Settings for COVID-19 Surge

- Providers are encouraged to minimize barriers to prescribing COVID-19 treatment prior to a Covid-19 surge by:
  - Working with residents' healthcare providers to specify patients' renal and hepatic function (whether normal or impaired)
  - Encourage providers to write orders for testing symptomatic residents
  - Make a plan for which treatment to prescribe if patients test positive
- Confirm pharmacy or infusion service provider supplies and options to accessing prescriptions.
- Encourage staff and providers to review the Surge Readiness Fact Sheet.

Updated COVID-19 Treatment Guidelines for Pregnancy

This summer updated guidelines for COVID-19 antiviral treatment for Pregnant and Lactating individuals was published on both the CDC and NIH treatment websites. Please look at the links below for the most up to date information.

Pregnancy, Lactation, and COVID-19 Therapeutics | COVID-19 Treatment Guidelines (nih.gov)

Special Clinical Considerations| Clinical Care Considerations | CDC

Public Communications Toolkit:
Handouts, Wallet Cards, Social Media, and More

Video







Provider Communications Toolkit:
Readiness Checklists, Best Practices Toolkits, and More



COVID-19 Therapeutics Best Practices Checklist

Guidance Topic	Checklist	Relevant
Testing	☐ **For symptomatic patients:** Share instructions on how to access same- or next-day testing. Note: A positive test is no longer required for oral COVID-19 therapeutic treatment if the clinical suspicion is high based on the patient's exposure history. ☐ **For symptomatic patients who test positive:** Emphasize that therapeutics are available, and recommended for most adults. Share instructions on how to access a same-day prescriber to discuss COVID-19 treatment. ☐ **Accept self-attestation of a positive COVID-19 test to facilitate care or prescribe therapeutics.**	How to get tested COVID-19 Respons
Prescribing	**A: Provider Education** ☐ Regularly share updates on COVID-19 therapeutics. ○ Ensure all relevant staff receive up-to-date information (via internal provider communication channels, using webinars, CME opportunities, and relevant listservs including CDPH's therapeutics updates). Set a regular cadence for sharing updates, such as a monthly provider meeting. ☐ Ensure all providers are aware of the California Health Advisory (summarized in Appendix 5) addressing several of the most common clinical misperceptions about COVID-19 therapeutics. ☐ Direct providers to helpful guidance, which includes tables reviewing therapeutics treatment options and clinical decision aids.	CDPH COVID-19 Th webpages While the COVID-19 Provider Warmline available, recomme call **1-866-268-432** to receive free and clinical consultatio testing and treatm your cases online. CDC Risk of COVID- Hospitalization, an Group

COVID-19 Surge Readiness

Best Practices for Skilled Nursing Facilities

Saving lives and avoiding hospitalizations

Lives are being saved (and hospitalizations avoided) with timely COVID-19 treatments. Treatments are safe and effective, even with changing variants. Treatments can keep residents, clients and staff from developing severe disease and may help them test negative for COVID-19 sooner. Preparing before a positive COVID-19 case occurs will help residents and staff get treated faster.

This notice reminds providers that ALL long term care residents are considered at higher risk for severe COVID-19 and the decision to not prescribe COVID-19 treatment should be reserved for situations in which the risk of prescribing clearly outweighs the benefits of treatment in preventing hospitalization, death, and the potential for reduced risk of long COVID.

The California Department of Public Health (CDPH) COVID-19 Therapeutics Task Force wants to support you in getting ready for potential COVID-19 surges in your facility. CDPH understands that facilities do not control the actions and decision of individual health care providers. However, you can help facilitate treatments for your residents and staff with preparedness education, awareness, and getting the right plans into place. The CDPH COVID-19 Therapeutics Task Force is available to assist you with developing best practices and education for your situation. You can contact us at COVIDRxProviders@cdph.ca.gov or give us a call (833) 502-1245 from Monday to Friday 8am to 6pm. You can also use the Provider COVID-19 Call Center email: covidcallcenter@cdph.ca.gov.

Surge preparedness tips: baseline strategies

- Encourage wearing masks with good fit and filtration like N95s, KN95s and KF94s
- Isolating and cohorting ill patients
- Testing staff and residents with symptoms
- Preparing for increasing use of COVID-19 treatments:
  1. Reach out to your residents' health care providers
  2. Confirm supply with your pharmacy, if possible
  3. Develop a plan
  4. Educate your staff
  5. Inform resident/resident representatives of treatment availability

July2023 • © 2023, California Department of Public Health

March 2023 • © 2023, California Department of Public Health

COVID-19 Surge Readiness: **Long Term Care Facilities**

Outreach to providers caring for your residents:

minder to Lower Barriers to Prescribing
22)
dents and make a plan for which
19 and have symptoms.
eaching out with positive test results).
m care pharmacy supplier or in-house
ion center for accessing IV treatments for
ming rapid COVID-19 and flu tests on
plan for positive results from rapid test
ing is not possible, request orders for
the event the result is positive.
communicating with providers about
t do you want for this patient."
atment they want for their loved ones.
or telehealth options for residents or staff
within 24 hours of testing positive:
p (sesamecare.com/covidca).
-19 positive, symptomatic patients if no
d. Some SNFs have adequate
d nurses do infusions on



Please...
KEEP DOORS
CLOSED
AT ALL TIMES



ETN Medical Infusion - Vaccine Clinics at Anaheim and Fountain Valley Offices

ETN Medical Infusion - Vaccine Clinics at Anaheim and Fountain Valley Offices

Riverside University HEALTH SYSTEM Public Health
SUPPORT
COUNTY OF RIVERSIDE
EMD



COVID-19 Oral Antivirals Commercialization

Edward Salaguinto, PharmD, RPh, CDPH

COVID-19 Oral Antivirals

COVID-19 Oral Antiviral	Paxlovid (nirmatrelvir/ritonavir)	Lagevrio (molnupiravir)
Commercialization Date	Before end of this year to mid-summer 2024	Anticipated November 2023
FDA Approval or EUA	FDA Approved, however, only product currently in circulation is EUA product	EUA Only (for now)
BAP (uninsured or underinsured)	Pfizer Patient Assistance Program	Merck Patient Assistance Program
Expiration Dates	Shelf-Life Extension for Specific Lots of Paxlovid (hhs.gov)	Shelf-Life Extension for Lagevrio (hhs.gov)

COVID-19 Oral Antivirals

Message from the CDPH Warehouse Team:

"In 2022, the total number of hospitalizations was higher than those experienced prior to the COVID-19 pandemic. As we transition into the 2023 fall influenza, RSV, and COVID-19 season, the CDC is warning of another "tripledemic", similar to last year's. We expect COVID-19 therapeutic allocations to remain static in the coming months, but the CDPH warehouse has an available stockpile of Paxlovid, Paxlovid Renal, and Molnupiravir which we can provide directly to providers/local health departments in addition to their weekly allocation. Expiry dates are similar to those therapeutics shipped by Cencora (formerly known as AmerisourceBergen)."

If you need extra/above allocation:

Please provide with the following information to your reply in the weekly email body and not directly on the Order Sheet:

- Provider Pin
- County
- Provider Name
- Product name and quantity

❖ Please ensure your inventory is updated in HPOP to keep the **COVID-19 Therapeutics Locator** accurate.

FLU
STATION
1

Stay Safe
RELAX AND
ENJOY A

ACPHD at APEB (AIDs Project of the East Bay)

Trinity County

ACPHD at the Fairgrounds in Pleasanton February 2021

"V-Day" December 2020 at St. Rose Hospital

Lynn, LB the Vintage NP from Lake County

Susan Senzaki, CSU Fresno

Tam Schuman, MD,
Clinical Professor, UCSF

Ceferina Engel, San Francisco

COVID-19 vaccine clinics that Memorial Care held for our community. Saddleback, CA

COVID-19 vaccine clinics that Memorial Care held for our community. Saddleback, CA

Ann Walker of Kern County Public Health ac
COVID-19 Vaccine to Public Health Director

Congratulations! Ann Walker 25 years with Kern C

Kern County Public Health PSA

Kern County: Early vaccine team: Jaz, Kim, Sara & Ann

Kern County Pediatric Clinic

Resources

Leslie Amani, CDPH

COVID-19 Vaccine Provider FAQs

- **Answers to provider questions**
- **Updated 9/14/2023**
- **Currently in its 132nd iteration!**

New ***Q: Following FDA authorization and CDC recommendations for the updated 2023-2024 COVID-19 vaccines, are bivalent mRNA COVID-19 vaccines still authorized for use?***

A: No. Bivalent mRNA COVID-19 vaccines are no longer authorized for use. To prevent vaccine administration errors, Providers should report and dispose of COVID-19 vaccines:

- Remove all bivalent mRNA COVID-19 vaccines from storage units regardless of expiration dates.
- Dispose of all bivalent mRNA COVID-19 vaccine vials in pharmaceutical waste containers or comingled pharmaceutical/sharps waste containers in accordance with local regulations and practice protocols for the disposal of regulated medical waste.
- Inactive providers can now report waste in myCAvax. The waste reporting deadline is Saturday, September 30, 2023, by 11:59PM. Report vaccine products as "Waste" in myCAvax and use "Other" to add comment "deauthorized."



Provider FAQs on EZIZ

EZIZ COVID-19 Resources Page

Accessible from BAP Menu and EZIZ Home Page!

Vaccine Information

- COVID-19 Vaccine Access & Ordering infographic
- COVID-19 Product & Timing Guides (**Updates coming soon!)**
- EUA Fact Sheets, package inserts, FDA pages, manufacturer websites
- General resources including guidance about fall products from FDA & CDC

Vaccine Administration

Communicating with Patients

- Resources for Patients
- Vaccine Confidence



COVID-19 Vaccine Resources

This landing page provides vaccine-specific resources to support all programs that supply COVID-19 vaccines. Relevant links are still being moved from the former EZIZ/COVID page. Please check back!

Vaccine Information

There is not a COVID-19 Vaccine Information Statement. Federal law allows up to 6 months for a new VIS to be used. EUA Fact Sheets for Recipients should be provided to patients at the time of vaccination for approved vaccine products. (See CDC guidance.)

- COVID-19 Vaccine Access & Ordering (Infographic)
- COVID-19 Vaccine Product Guide
- COVID-19 Vaccine Timing Guide | Spanish

Pfizer-BioNTech (2023-24 COVID-19 Vaccine, mRNA)

- Approval of Comirnaty for 12Y+: Provider Letter | Package Insert | COMIRNATY (FDA)
- Authorization under EUA for 6M-11Y: Provider Letter | Fact Sheet for HCPs | Fact Sheet for Recipients & Caregivers | Pfizer-BioNTech COVID-19 Vaccine (FDA)
- Websites: Manufacturer | CDC Resources

Moderna (2023-24 COVID-19 Vaccine, mRNA)

- Approval of Spikevax for 12Y+: Provider Letter | Package Insert | FDA page
- Authorization under EUA for 6M-11Y: Provider Letter | Fact Sheet for HCPs | Fact Sheet for Recipients & Caregivers | Moderna COVID-19 Vaccine (FDA)
- Websites: Manufacturer | CDC Resources

Novavax (2021 COVID-19 Vaccine, Adjuvanted)

- Authorization under EUA for 12Y+: Fact Sheet for HCPs | Fact Sheet for Recipients & Caregivers | Novavax COVID-19 Vaccine (FDA)
- Websites: Manufacturer | CDC Resources

General Resources

- CDC Recommends Updated COVID-19 Vaccine for Fall/Winter Virus Season (CDC)
- Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants (FDA)
- Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023 (FDA)
- Resources for the Fall Respiratory Illness Season (COVID-19, Flu and RSV) (FDA)

Vaccine Administration

- Interim Clinical Considerations for Use of COVID-19 Vaccines (CDC)
- ACIP Recommended Immunization Schedules: Child and Adolescent | Adult (CDC)
- Coadministration of COVID-19 Vaccines (CDC) | Coadministration Tips (graphic)
- Reporting Adverse Events to VAERS
- Reporting Race & Ethnicity
- Tips to Ease Anxiety During Vaccination
- Vaccine Administration Checklist (to be updated after FDA authorizations)
- More Job Aids

Communicating with Patients

- COVID-19 Vaccine Resources for Patients
- COVID-19 Vaccine Confidence

CA Bridge Access Program: At a Glance



Requirements at a Glance

This document will be continuously updated as information and new resources become available.

COVID-19 vaccine product and CDC's Vaccine Product Training will be posted after FDA authorization/CDC recommendation.

Who's Eligible: Providers serving uninsured/underinsured adults through public health departments, Federally Qualified Health Centers (FQHCs)/Rural Health Centers, tribal clinics, Indian Health Services sites, and additional providers deemed eligible by LHDs

What You Need to Know: The California Bridge Access Program provides no-cost COVID-19 vaccines to uninsured/underinsured adults (19 years and older) served by enrolled and approved providers. Vaccine supply is limited. Insured patients—including patients covered by Medicare and Medi-Cal—are NOT eligible. Providers must conduct eligibility screening and proper documentation with each administration to ensure vaccines go to eligible adults. Limited supplies of the updated monovalent (XBB subvariant) COVID-19 vaccine will be provided through two components of the state program:

Program Components:

- Public Health Component: Coordinated by State Immunization Programs, in collaboration with existing public health infrastructure. CDPH will allocate to each LHD doses of COVID-19 vaccines based on federally provided vaccine purchase funding limits. Doses allocated will support vaccination of uninsured and under-insured populations at local health departments, FQHCs/RHCs, Tribal and IHS clinics, and other safety net providers selected by LHDs for enrollment in the CA Bridge Access Program.
- Pharmacy component: Independently coordinated by CDC with 3 contracted pharmacy chains/organizations: CVS, Walgreens, and E-True North (for independent and other pharmacies), who will receive supplies replenished by the COVID-19 Vaccine manufacturers directly; the specific sites receiving vaccine are not yet determined, and enrollment information is still forthcoming. All information in this document addresses the public health component.

Topic	Requirements & Guidance	Resource Links
★	***What's new for existing COVID-19 providers?*** California's BAP Provider Participation Agreement replaces the federal COVID-19 Provider Agreement. While most requirements remain the same, look for orange stars identifying new requirements and job aids to assist you.	
Primary Documents	• BAP Provider Participation Agreement • BAP Provider Operations Manual (and Startup Worksheet for new providers) • COVID-19 Vaccine Commercialization FAQs	

BAP Requirements at a Glance

Overview document links requirements and guidance to new resources!

Topics include:

- Provider Participation Agreement
- Required Vaccine Product Training
- Storage and Handling
- Reporting
- Vaccine Product Information
- Fact Sheets
- Much more to explore!

CA Bridge Access Program Provider Operations Manual

This manual provides step-by-step instructions and links to available resources.

Audience:

- Existing COVID-19 vaccine providers new to BAP
- New BAP organizations & locations

Startup Worksheet
(for new organizations & locations)



New EZIZ BAP Resources Page!

Eligibility Screening & Documentation


Eligibility Based on Insurance Status

BAP

Bridge Access Program

A limited supply of COVID-19 vaccine will be made available through the Bridge Access Program for uninsured and underinsured adults (19 years and older) to prevent loss of access when vaccines transition to the commercial market. Insured patients—including patients covered by Medicare and Medi-Cal—are **NOT** eligible for the COVID-19 vaccines provided through this program. This temporary program will sunset at the end of 2024.

✓ Eligible for COVID-19 Vaccine through BAP (317 Funds)

Patient health insurance status:

- **Uninsured/No insurance** (includes those who receive primary care through county safety net programs; these are NOT considered health insurance)
- **Underinsured** (has health insurance, but the insurance does not include any vaccines; insurance covers only selected vaccines; insurance does not provide first-dollar coverage for vaccines.)
- **Insurance NOT through Medi-Cal or Medicare** (only eligible for COVID-19 vaccines if **NOT** covered by patient's private insurance plan)[1]

✗ Not Eligible for COVID-19 Vaccine through BAP (317 Funds)

Patient health insurance status:

- **Medi-Cal Fee-For-Service/Medi-Cal Managed Care** (list is/CAhealthplans)
- **Medicare Part B (medical benefit) AND Part D (prescription drug benefit)**
- **Medicare Part B Alone**
- **Medicare Part D Alone**
- **Insurance NOT through Medi-Cal or Medicare**[1]

1. Fully insured adults whose insurance covers the cost of the vaccine(s) are NOT eligible for COVID-19 vaccine—even if the insurance includes a high deductible or co-pay, the plan's deductible has not been met, or the insurance has cost sharing.

California Department of Public Health, Immunization Branch IMM-1473 (9/23)

[Eligibility Cheat Sheet]

317 (VFA & BAP) Eligibility Screening & Documentation Requirements

317 BAP VFA

1. Screen for Eligibility

Eligibility screening must be conducted prior to the administration of any 317-funded vaccine (e.g., Vaccines for Adults and Bridge Access Program). Eligibility is self-reported by the patient and verification of eligibility can be obtained verbally from the patient.

✓ **Eligible for VFA and/or BAP (COVID) vaccines if at least 19 years of age and**

1. Has no insurance, or
2. Is underinsured (public or private health insurance does not cover all vaccines or covers vaccines with a fixed dollar limit which has been reached)

✓ **Eligible for certain VFA vaccines if at least 19 years of age and**

3. Has Medicare **Part B**, but **NOT Part D**, patient is eligible for:
   - Hep A
   - Hep B (if considered low risk for Hep B)
   - HPV, MMR, Varicella, and Zoster
   - Td (if no wound exposure) and Tdap
4. Has Medicare **Part D**, but **NOT Part B**, patient is eligible for:
   - Hep B, PCV20

2. Document Patient's Eligibility

There are three important elements to include when you document a patient's eligibility:

1. Date of screening
2. If patient is eligible for the Vaccines for Adults (VFA) and/or Bridge Access Program (BAP)
3. If patient is eligible AND at least 19 years of age, document which of the criterion above is met

3. Use a Compliant Record Keeping System

- **CAIR and Electronic Health/Medical Record (EHR/EMR)**
  Note: If your practice's EMR/EHR does not capture all the necessary screening elements, they may be documented in the system's notes section.
- **CAIR and 317 Eligibility Screening Form (IMM-1226)**

Make sure to maintain patient eligibility screening records for a minimum of 3 years. Refer to the 317 CAIR Documentation Requirement.

4. Communicate the Patient's Eligibility

All staff should be knowledgeable of eligibility. Ensure practice protocols are in place so vaccinators know when to use 317-funded versus private vaccines.

California Department of Public Health, Immunization Branch IMM-1476 (8/31/23)

[Step-by-step Instructions]
(includes options for reporting to CAIR)


317 (VFA & BAP) Eligibility Screening Record for Adult Patients

At each immunization visit, determine if patients are eligible for COVID-19 vaccines (if participating in the Bridge Access Program) and/or other routinely recommended vaccines through 317 funds (e.g., VFA).

Patient Information

Patient Name (Last, First, MI): _____ Date of Birth: _____

Provider Name: _____

Eligibility Criteria for 317-Funded Vaccines (e.g., VFA and BAP)

✓ **Eligible for VFA and/or BAP (COVID) vaccines if at least 19 years of age and**

1. Has no insurance, or
2. Is underinsured (public or private health insurance does not cover all vaccines or covers vaccines with a fixed dollar limit which has been reached)

✓ **Eligible for certain VFA vaccines if at least 19 years of age and**

3. Has Medicare **Part B**, but **NOT Part D**, patient is eligible for:
   - Hep A
   - Hep B (if considered low risk for Hep B)
   - HPV, MMR, Varicella, and Zoster
   - Td (if no wound exposure) and Tdap
4. Has Medicare **Part D**, but **NOT Part B**, patient is eligible for:
   - Hep B, PCV20

Document Patient's Eligibility

Write the screening date and check appropriate status. (Note: verification of responses is not required. Keep this record for at least 3 years and make it available to state or federal officials upon request).

Screening Date	✓ Eligible for VFA and BAP (COVID) (No insurance)	✓ Eligible for VFA and BAP (COVID) (Underinsured)	✓ Eligible for some VFA vaccines (Medicare Part B or Part D only)	✗ Not Eligible for BAP (COVID) (Medicare Part B or Part D only)	✗ Not Eligible for VFA or BAP (COVID) (Both Medicare Part B & D or insurance pays for vaccines*)
	☐	☐	☐Part B ☐Part D	☐Part B ☐Part D	☐
	☐	☐	☐Part B ☐Part D	☐Part B ☐Part D	☐
	☐	☐	☐Part B ☐Part D	☐Part B ☐Part D	☐
	☐	☐	☐Part B ☐Part D	☐Part B ☐Part D	☐
	☐	☐	☐Part B ☐Part D	☐Part B ☐Part D	☐
	☐	☐	☐Part B ☐Part D	☐Part B ☐Part D	☐

*Note: adults enrolled in Medi-Cal or Medi-Cal Managed Care are considered insured.

California Department of Public Health, Immunization Branch IMM-1226 (8/29/23)

[Screening Record]
(for small practices with no EHR)

BAP Resources

Program Participation

- Requirements at a Glance
- Provider Operations Manual (POM)
- Required Vaccine Product Training

Eligibility Screening & Documentation

- BAP Eligibility Based on Insurance Status
- 317 (VFA & BAP) Eligibility Screening and Documentation Requirements
- 317 (VFA & BAP) Eligibility Screening Record | Spanish
- VFA & BAP Patient Vaccine Poster | Spanish
- Vaccine Program Eligibility Guidelines (for Community Health Centers)
- CAIR Requirement for Documenting 317-Funded Vaccines

2023-24 COVID-19 Vaccine Information

Please see EZIZ's COVID-19 Vaccine Resources for vaccine administration job aids plus materials from FDA, CDC and vaccine manufacturers.

[BAP Resources]

Commercialization at a Glance: Provider Transition Guide



Commercialization at a Glance: Provider Transition Guide

California COVID-19 Vaccination Program

Commercialization is the transition of COVID-19 medical countermeasures—vaccines, treatments, and test kits—previously purchased by the U.S. Government (USG) to established pathways of procurement, distribution, and payment by both public and private payers. This guide summarizes the HHS Commercialization Transition Guide, HHS Bridge Access Program Fact Sheet, and CDPH guidance as the USG prepares to stop distributing COVID-19 vaccines and vaccines transition to the commercial market. Updated topics highlighted below. Sections include:

- Fall Transition Timeline
- Sunsetting of the Federal COVID-19 Vaccination Program
- Commercialization of COVID-19 Vaccines
- Anticipated Vaccination Schedule for the Fall

Topic	Guidance	Effective Date
Section 1	Fall Transition Timeline	
	Week of July 31, 2023: • CDC set vaccine thresholds to -0- in anticipation of decreased vaccine demand. • Providers were asked to order a 2-month vaccine supply to last until new products are approved by FDA. • Vaccine doses can still be ordered by States, but the processes, timing, and cadence for ordering processing will change. Based on doses ordered, we ask CDC for allocations, wait 1-3 days for doses, then transmit orders to CDC. August 3-Early September: • Providers may still submit additional Small Orders if needed. But these are NOT sent to CDC. These are fulfilled locally/TPR. • Larger orders are now only available to LHDs/MCEs. • ALL healthcare providers are advised to begin planning, prebooking or procuring COVID-19 vaccine doses for privately insured individuals. • States begin to plan closeout of USG COVID-19 Program, and implementation of much smaller Bridge Access Program, and addition of COVID-19 vaccines to VFC Programs. TBD (expected early to mid-September): • FDA decisions and amendments to Emergency Use Authorizations (EUAs) / Biologics License Applications (BLAs). Approve new products, and de-authorized current products. • Concurrently, USG WILL discontinue distribution of current COVID-19 vaccine composition. • Advisory Committee on Immunization Practices (ACIP) discussion on COVID-19 epidemiology and vaccine effectiveness and CDC recommendation. • CDPH and LHDs work on BAP provider enrollment, and prepare for COVID-19 ordering for BAP Provider and VFC Providers. TBD (ACIP Recommendation + 2 weeks=Late September/Early October): • Fall vaccine availability for administration begins across all eligible age groups, with corresponding vaccine supply based on insurance coverage, and eligibility (for providers participating in VFC or CA's Bridge Access Program). • Providers will dispose of any remaining supply of de-authorized COVID-19 vaccines.	

California Department of Public Health, IZ Branch 1 IMM-1467 (9/8/23)

Updated: 9.8.23

CDPH has created a multiple-page "Commercialization Provider Transition Guide".

The current information, and other resources, can be found on EZIZ.org using this link: Commercialization at a Glance: Provider Transition Guide

COVID-19 Vaccine Locations



Need help finding a COVID-19 vaccine in the U.S.? Call 1-800-232-0233 (TTY 1-888-720-7489)

https://www.vaccines.gov/

Guidance for Reporting to Vaccines.gov

Key Information:

- Providers agree to make their BAP location visible so eligible recipients (uninsured and underinsured) can find no-cost vaccines.

- No inventory reporting is required

CAIRS Help Desk
800-578-7889
CAIRHelpDesk@cdph.ca.gov
Monday- Friday, 8:00AM-5:00PM



COVID-19 Vaccine Support

Provider Call Center

Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: myCAvax.hd@cdph.ca.gov
- For My Turn Clinic Help Desk inquiries: MyTurn.Clinic.HD@cdph.ca.gov
- For all other inquiries: providercallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below. Need help? View our jobs aids in the Knowledge Center, or contact us.



COVID-19 Therapeutics Resources

Type of Support	Description	Updated 8.31.23
Clinical Guidance	As of August 31, the COVID-19 Therapeutics Warmline: **1-866-268-4322 (866-COVID-CA) is no longer staffed for provider COVID-19 Therapeutics questions. For general question Therapeutics questions, please email:** COVIDRxProviders@cdph.ca.gov	
General Information	CDPH COVID-19 Treatments Webpage (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources) CDPH COVID-19 Treatments Job Aid (questions and answers for the public on COVID-19 therapeutics) COVID-19 Therapeutics Best Practices Checklist (testing, prescribing, dispensing, and more) Frequently Asked Questions document for clinics, providers, and pharmacists	
Locating Resources	Finding Providers and Test-to-Treat Sites • COVID-19 Therapeutics Locator (arcgis.com) • Test-to-Treat (hhs.gov)	
LHJ Therapeutics SharePoint	Primary source for recorded webinars, slides, datasets and HPOP reporting information. (For access, email JEOCuser54@cdph.ca.gov) • Therapeutic Weekly Email Update files (SharePoint) • CDPH Therapeutics HPoP Account Verification & Reporting information	
Questions	For general CDPH Therapeutics questions, please email COVIDRxProviders@cdph.ca.gov For ordering, program inquiries, signing up new HPOP Accounts: please e-mail CDPHTherapeutics@cdph.ca.gov	

CDPH Provider Webinars and Trainings

Week of October 2, 2023

	Monday 10/2	Tuesday 10/3	Wednesday 10/4	Thursday 10/5	Friday 10/6
Live Webinars and Training					CDPH Immunization Updates for Providers *9:00 am – 10:30 am*
View On Demand	• Intro to My Turn Onboarding *(v. 1/4/22)* • CDPH Weekly Provider Webinars Archived Recordings and Slides		• myCAvax Release Notes for LHJs and CDPH Users (*Requires myCAvax Login)* • Latest Features in myCAvax for Providers (*Requires myCAvax Login)* • COVID-19 Crucial Conversations Archived Webinars and Slides		• Moderna COVID-19 Vaccine Resources for Providers • CDC COVID-19 Vaccine Webinar Series • California Immunization Coalition COVID Conversation Series • AIM Vaccine Confidence Toolkit Webinar Series
Help	***Help Desk*** myCAvax Help Desk Email: mycavax.hd@cdph.ca.gov My Turn Help Desk Email: myturn.clinic.hd@cdph.ca.gov My Turn Onboarding Email: myturnonboarding@cdph.ca.gov		***General*** CDPH Provider Call Center: 1-833-502-1245, 8am-5pm, Mon-Fri Email: providercallcenter@cdph.ca.gov Vaccines: COVID-19 Vaccines Therapeutics: COVID-19 Therapeutics		***Mpox*** Email: stdcb@cdph.ca.go General Website: Mpox Website Vaccines: Mpox Vaccines Website

COVID-19 Vaccine Trivia

The State of California's vaccination efforts benefited from partnerships with

- ❑ Promotoras
- ❑ Faith-based organizations
- ❑ Community-based organization
- ❑ All of the above

COVID-19 Vaccine Trivia

The State of California's vaccination efforts benefited from partnerships with

- ❑ Promotoras
- ❑ Faith-based organizations
- ❑ Community-based organization
- ☑ All of the above

Promotoras, San Diego

SONYA
HARRIS
GRIT





WWFD

Sharing and Q&A

Questions

During today's session, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.

Resource links will be dropped into, “Chat”

Upcoming Webinar Opportunities

CDPH Immunization Updates for Providers

Next session: Friday, October 6, 2023

9AM – 10:30AM

Friday Provider Webinar Support

December 2020 – Present Day

Webinar Support Team Members

Cecilia LaVu, Michael Fortunka, Leslie Amani, Rachel Jacobs, Blanca Corona, Charles Roberts, Billie Dawn Greenblatt, Meril Lavezzo, Jane Grey, Rebeca Boyte, Hailey Ahmed, Grace Malson, Mimi Tran, Hilary Fong, Reva Anderson, Tehwan Park, Samuel Kerr, Diane Evans, and Kerry Wood

Webpage Support and Resources

Troy Parrish, Natalie Nakahara, Anya Gutman, Kerdlyn Henry, and Chi Siu

A special thank you to myriad COVID-19 presenters, partners, and subject matter experts!

We wish to thank COVID-19 Providers throughout the State of California. Your efforts opened windows of hope during the pandemic. California reopened has been changed for the better because of you! …and, as always, we wish you all the best, as we continue to work together to vaccinate California!